Literature DB >> 7621849

Elimination of amrinone during continuous veno-venous haemofiltration after cardiac surgery.

A Hellinger1, K Wolter, G Marggraf, R Pentz, E Fritschka.   

Abstract

We studied the elimination of amrinone during continuous veno-venous haemofiltration (CVVHF) in three anuric patients after cardiac surgery. The patients had developed low cardiac output followed by acute prerenal failure. Plasma amrinone levels measured by HPLC were fitted to a two-compartment model. We found significant amrinone clearance, with a mean sieving coefficient (S) of 0.44%, which correlates with the protein-unbound, pharmacologically effective fraction of amrinone. The AUC of the arterial plasma concentration-time curve was decreased by 49.8%. All pharmacokinetic parameters showed wide interindividual variation. To ensure the therapeutic effect of amrinone and to avoid toxic adverse effects monitoring of plasma amrinone levels is necessary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7621849     DOI: 10.1007/bf00202173

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Newer oral inotropic agents: phosphodiesterase inhibitors.

Authors:  K Chatterjee
Journal:  Crit Care Med       Date:  1990-01       Impact factor: 7.598

Review 2.  Use of inotropes in the critical care setting.

Authors:  H Löllgen; H Drexler
Journal:  Crit Care Med       Date:  1990-01       Impact factor: 7.598

3.  High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog.

Authors:  M P Kullberg; B Dorrbecker; J Lennon; E Rowe; J Edelson
Journal:  J Chromatogr       Date:  1980-01-04

4.  Amrinone metabolism.

Authors:  M P Kullberg; G B Freeman; C Biddlecome; A A Alousi; J Edelson
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

5.  Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure.

Authors:  A Davenport; E J Will; A M Davidson
Journal:  Crit Care Med       Date:  1993-03       Impact factor: 7.598

6.  Effect of continuous arteriovenous haemofiltration on pharmacokinetics of amrinone.

Authors:  S Lawless; I Restaino; S Azin; D Corddry
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 7.  Amrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-12       Impact factor: 9.546

8.  Hemodynamic effects of enoximone in cardiac surgery patients.

Authors:  J Boldt; H A Dieterich; D Kling; G Hempelmann
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

  8 in total
  1 in total

Review 1.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.